Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma

Hepatology

Volumn 56, Issue 4, 2012, Pages 1380-1390

  Li, Li ^a,b   Jin, Ronghua ^b   Zhang, Xiaoli ^c   Lv, Fudong ^b   Liu, Lifeng ^a   Liu, Daojie ^a   Liu, Kai ^a   Li, Ning ^b   Chen, Dexi ^a,b  

^a Beijing Institute of Liver Disease   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYPICAN 3; LUCIFERASE; MESSENGER RNA;

ADULT; AGED; ARTICLE; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE C MYC; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOPSY, NEEDLE; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYPICANS; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; TISSUE CULTURE TECHNIQUES; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84867161026     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25891     Document Type: Article

References (35)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol 2009; 34: 649-656.
4. Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res 1997; 57: 5179-5184.
5. Jakubovic BD, Jothy S. Glypican-3: from the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma. Exp Mol Pathol 2007; 82: 184-189.
6. Filmus J. Glypicans in growth control and cancer. Glycobiology 2001; 11: 19R-23R.
7. Filmus J, Capurro M. The role of glypican-3 in the regulation of body size and cancer. Cell Cycle 2008; 7: 2787-2790.
8. Hann SR. Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function. Semin Cancer Biol 2006; 16: 288-302.
9. Cowling VH, Cole MD. Mechanism of transcriptional activation by the Myc oncoproteins. Semin Cancer Biol 2006; 16: 242-252.
10. O'Connell BC, Cheung AF, Simkevich CP, Tam W, Ren X, Mateyak MK, et al. A large scale genetic analysis of c-Myc-regulated gene expression patterns. J Biol Chem 2003; 278: 12563-12573.
11. Chen D, Padiernos E, Ding F, Lossos IS, Lopez CD. Apoptosis-stimulating protein of p53-2 (ASPP2/53BP2L) is an E2F target gene. Cell Death Differ 2005; 12: 358-368.
12. Chen D, Yu Z, Zhu Z, Lopez CD. E2F1 regulates the base excision repair gene XRCC1 and promotes DNA repair. J Biol Chem 2008; 283: 15381-15389.
13. Huber R, Crisponi L, Mazzarella R, Chen CN, Su Y, Shizuya H, et al. Analysis of exon/intron structure and 400 kb of genomic sequence surrounding the 5′-promoter and 3′-terminal ends of the human glypican 3 (GPC3) gene. Genomics 1997; 45: 48-58.
14. Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 2009; 100: 1403-1407.
15. Arvanitis C, Felsher DW. Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin Cancer Biol 2006; 16: 313-317.
16. Peng SY, Lai PL, Hsu HC. Amplification of the c-myc gene in human hepatocellular carcinoma: biologic significance. J Formos Med Assoc 1993; 92: 866-870.
17. Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005; 65: 6245-6254.
18. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, Da CL, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-1512.
19. Morford LA, Davis C, Jin L, Dobierzewska A, Peterson ML, Spear BT. The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and homeoboxes 2 and in the regenerating liver by alpha-fetoprotein regulator 2. HEPATOLOGY 2007; 46: 1541-1547.
20. Lai JP, Sandhu DS, Yu C, Han T, Moser CD, Jackson KK, et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. HEPATOLOGY 2008; 47: 1211-1222.
21. Carloni G, Champ B, Vilarem MJ, Lavialle C, Cassingena R. Activation of c-Ki-ras coexists with c-myc amplification in cells from a nude mouse tumor induced by the human breast carcinoma cell line SW 613-S. FEBS Lett 1988; 233: 268-272.
22. Chan KL, Guan XY, Ng IO. High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma. Hum Pathol 2004; 35: 1324-1331.
23. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000; 14: 2501-2514.
24. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 1993; 5: 56-61.
25. Zhang X, Farrell AS, Daniel CJ, Arnold H, Scanlan C, Laraway BJ, et al. Mechanistic insight into Myc stabilization in breast cancer involving aberrant Axin1 expression. Proc Natl Acad Sci U S A 2011.
26. Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, Llovet JM. Cancer gene discovery in hepatocellular carcinoma. J Hepatol 2010; 52: 921-929.
27. Filmus J, Capurro M, Rast J. Glypicans. Genome Biol 2008; 9: 224.
28. Torisu Y, Watanabe A, Nonaka A, Midorikawa Y, Makuuchi M, Shimamura T, et al. Human homolog of NOTUM, overexpressed in hepatocellular carcinoma, is regulated transcriptionally by beta-catenin/TCF. Cancer Sci 2008; 99: 1139-1146.
29. Cheng W, Tseng CJ, Lin TT, Cheng I, Pan HW, Hsu HC, et al. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway. Carcinogenesis 2008; 29: 1319-1326.
30. Capurro MI, Xu P, Shi W, Li F, Jia A, Filmus J. Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev Cell 2008; 14: 700-711.
31. Sancho E, Batlle E, Clevers H. Live and let die in the intestinal epithelium. Curr Opin Cell Biol 2003; 15: 763-770.
32. Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000; 103: 311-320.
33. Cairo S, Armengol C, De Reynies A, Wei Y, Thomas E, Renard CA, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008; 14: 471-484.
34. Reed KR, Athineos D, Meniel VS, Wilkins JA, Ridgway RA, Burke ZD, et al. B-catenin deficiency, but not Myc deletion, suppresses the immediate phenotypes of APC loss in the liver. Proc Natl Acad Sci U S A 2008; 105: 18919-18923.
35. Cadoret A, Ovejero C, Saadi-Kheddouci S, Souil E, Fabre M, Romagnolo B, et al. Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. Cancer Res 2001; 61: 3245-3249.